Public Profile

Nektar Therapeutics

Nektar Therapeutics, a leading biopharmaceutical company headquartered in the United States, focuses on innovative drug development to address unmet medical needs. Founded in 1990, Nektar has made significant strides in the industry, particularly in the fields of oncology, immunology, and pain management. The company is renowned for its proprietary drug delivery technologies, which enhance the efficacy and safety of therapeutic agents. Nektar's core products, including its advanced therapies for cancer and chronic pain, stand out due to their unique mechanisms of action and patient-centric design. With a strong market position, Nektar Therapeutics has achieved notable milestones, including strategic partnerships and a robust pipeline of clinical candidates, solidifying its reputation as a pioneer in the biopharmaceutical landscape.

DitchCarbon Score

How does Nektar Therapeutics's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

25

Industry Average

Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

30

Industry Benchmark

Nektar Therapeutics's score of 25 is lower than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.

0%

Let us know if this data was useful to you

Nektar Therapeutics's reported carbon emissions

Nektar Therapeutics, headquartered in the US, currently does not have publicly available carbon emissions data or specific reduction targets. Without emissions figures, it is challenging to assess their carbon footprint or the scope of their emissions (Scope 1, 2, or 3). Additionally, there are no documented climate commitments or initiatives aimed at reducing their environmental impact. As the industry increasingly prioritises sustainability, Nektar Therapeutics may need to establish clear climate goals and reporting practices to align with global standards and stakeholder expectations.

Industry emissions intensity

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Nektar Therapeutics's primary industry is Pharmaceutical Preparation Manufacturing, which is very low in terms of carbon intensity compared to other industries.

Location emissions intensity

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for Nektar Therapeutics is in US, which has a low grid carbon intensity relative to other regions.

Reduction initiatives & disclosure networks

Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.

Nektar Therapeutics is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Similar Organizations

SunBio,Inc.

KR
Health and social work services (85)
Updated about 8 hours ago

Dr Reddys Laboratories

IN
Pharmaceutical Preparation Manufacturing
Updated about 8 hours ago

Assertio Holdings, Inc.

US
Pharmaceutical Preparation Manufacturing
Updated about 8 hours ago

SciSparc Ltd.

IL
Health and social work services (85)
Updated about 8 hours ago

Lifecycle Pharma, Inc.

US
Updated 3 months ago
DitchCarbon Score

Ironwood Pharmaceuticals, Inc.

US
Pharmaceutical Preparation Manufacturing
Updated about 8 hours ago

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers